Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers
Diepstraten et al. demonstrate that p53 enforces apoptosis induced by BH3-mimetic drugs. To boost BH3-mimetic-induced apoptosis in TP53-mutant blood cancers, STING agonists were employed to induce pro-apoptotic BH3-only protein expression in a p53-independent manner. Therefore, BH3-mimetics alongside STING agonists represents a promising new combination therapy for aggressive TP53-mutant blood cancers.